{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:29:28Z","timestamp":1779892168945,"version":"3.53.1"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The primary objective of the study was to determine the bioavailability of 2 new formulations of azelastine (AZE) hydrochloride (0.10% and 0.15% AZE) containing sorbitol and sucralose compared with the commercially available 0.10% AZE. This study was performed\u00a0in healthy volunteers based on the pharmacokinetic parameters maximum plasma concentration and area under the plasma concentration\u2013time curve from time zero to the last measurable concentration. This was a Phase 1, open\u2010label, single\u2010center, randomized, parallel\u2010group study. Subjects were randomized to 1 of 3 treatment groups: (1) 0.10% AZE (treatment A), (2) 0.15% AZE (treatment B) (Groups 1 and 2 both containing sorbitol and sucralose), and (3) the commercially available 0.10% AZE (treatment C). A total of 54 subjects were randomized and received treatment A, B, or C. Maximum plasma concentration and area under the plasma concentration\u2013time curve were similar when compared in treatments A and C (0.1%) for AZE and its metabolite, desmethylazelastine. The most frequently reported adverse events were rhinorrhea (5.6%) and sneezing (5.6%).<\/jats:p>","DOI":"10.1002\/cpdd.1498","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T05:40:01Z","timestamp":1736487601000},"page":"217-222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male Volunteers"],"prefix":"10.1002","volume":"14","author":[{"given":"Jean","family":"Bousquet","sequence":"first","affiliation":[{"name":"Institute of Allergology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"},{"name":"Allergology and Immunology Fraunhofer Institute for Translational Medicine and Pharmacology ITMP  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[{"name":"Center for Rhinology and Allergology  Wiesbaden Hessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Liu","sequence":"additional","affiliation":[{"name":"Global Clinical Pharmacology Mylan Pharmaceuticals Inc. (Now Viatris)  Canonsburg PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duc Tung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences MEDA Pharma GmbH &amp; Co KG (A Viatris Company)  Bad Homburg Hessen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh Kumar","family":"Ramalingam","sequence":"additional","affiliation":[{"name":"Mylan Pharmaceuticals Private Limited (Now Viatris)  Bengaluru India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgio Walter","family":"Canonica","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University  Milan Italy"},{"name":"Asthma &amp; Allergy Unit IRCCS Humanitas Research Hospital  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Berger","sequence":"additional","affiliation":[{"name":"Allergy &amp; Asthma Solutions  Coto de Caza CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01620.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.06.049"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.011"},{"key":"e_1_2_11_5_1","article-title":"Azelastine HCl: a review of the old and new formulations","volume":"2","author":"Horbal JM","year":"2010","journal-title":"Clin Med Insights Ther"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2009.30.3296"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2009.30.3284"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.20065"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1244012"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X226302"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.12239FP"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.59566\/IJBS.2010.6120"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.04.008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04222.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.12.689"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-013-0134-0"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(24)15227-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425250802670474"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938050-00005"},{"key":"e_1_2_11_20_1","volume-title":"Concepts in Clinical Pharmacokinetics","author":"DiPiro JT","year":"2010"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:40:02Z","timestamp":1741873202000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cpdd.1498"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1498","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"2024-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}